Clinical Trial Update: Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial entry outlines a Phase 1/2 study to determine the optimal dose and evaluate the safety and efficacy of PRG-N-01 in patients with Neurofibrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type Ii

Drugs mentioned

• PRG-N-01

Snippet

Sponsor: PRG Science & Technology Co., Ltd. | Conditions: Neurofibromatosis Type II, NF2 | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING